Aziyo Biologics will provide ViBone® cellular bone matrix to RTI Surgical for exclusive distribution in the U.S. Further, the companies will partner on new research for the product.
ViBone is a next-gen viable bone matrix designed to perform like high-quality autograft. ViBone is processed using a proprietary method designed to protect and preserve the health of native bone cells, thus potentially enhancing new bone formation.
Aziyo Biologics will provide ViBone® cellular bone matrix to RTI Surgical for exclusive distribution in the U.S. Further, the companies will partner on new research for the product.
ViBone is a next-gen viable bone matrix designed to perform like high-quality autograft. ViBone is processed using a proprietary method designed to...
Aziyo Biologics will provide ViBone® cellular bone matrix to RTI Surgical for exclusive distribution in the U.S. Further, the companies will partner on new research for the product.
ViBone is a next-gen viable bone matrix designed to perform like high-quality autograft. ViBone is processed using a proprietary method designed to protect and preserve the health of native bone cells, thus potentially enhancing new bone formation.
Source: Aziyo Biologics, Inc. and RTI Surgical, Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





